CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients

References

• Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization, 2020.
   Google Scholar
• Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(2):106–119. doi:10.1016/S2468-1253(20)30307-1.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok A, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800.
   PubMed Web of Science ®Google Scholar
• WHO: Global health sector strategy on viral hepatitis 2016-2021. World Health Organization, 2021.
   Google Scholar
• Bonanzinga S, Onelia F, Jackson K, et al. Multicenter clinical evaluation of alinity m HBV assay performance. J Clin Virol. 2020;129:104514. doi:10.1016/j.jcv.2020.104514.
   PubMed Web of Science ®Google Scholar
• Gupta E, Khodare A, Rani N, et al. Performance evaluation of Xpert HBV viral load (VL) assay: point-of-care molecular test to strengthen and decentralize management of chronic hepatitis B (CHB) infection. J Virol Methods. 2021;290:114063. doi:10.1016/j.jviromet.2021.114063.
   PubMed Web of Science ®Google Scholar
• Ishizaki A, Bouscaillou J, Luhmann N, et al. Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries. BMC Infect Dis. 2017;17(Suppl 1):696. doi:10.1186/s12879-017-2767-0.
   PubMedGoogle Scholar
• Tordrup D, Hutin Y, Stenberg K, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. Lancet Glob Health. 2019;7(9):e1180–e1188. doi:10.1016/S2214-109X(19)30272-4.
   PubMed Web of Science ®Google Scholar
• Reipold EI, Trianni A, Krakower D, et al. Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers. BMC Infect Dis. 2017;17(Suppl 1):702), doi:10.1186/s12879-017-2769-y.
   PubMedGoogle Scholar
• Park HD. Current status of clinical application of point-of-care testing. Arch Pathol Lab Med. 2021;145(2):168–175. doi:10.5858/arpa.2020-0112-RA.
   PubMed Web of Science ®Google Scholar
• Boonkaew S, Yakoh A, Chuaypen N, et al. An automated fast-flow/delayed paper-based platform for the simultaneous electrochemical detection of hepatitis B virus and hepatitis C virus core antigen. Biosens Bioelectron. 2021;193:113543), doi:10.1016/j.bios.2021.113543.
   PubMed Web of Science ®Google Scholar
• Liu YP, Yao CY. Rapid and quantitative detection of hepatitis B virus. World J Gastroenterol. 2015;21(42):11954–11963.
   PubMed Web of Science ®Google Scholar
• Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356(6336):438–442.
   PubMed Web of Science ®Google Scholar
• Ning B, Yu T, Zhang S, et al. A smartphone-read ultrasensitive and quantitative saliva test for COVID-19[J]. Sci Adv, 2021, 7(2). doi:10.1126/sciadv.abe3703.
   Web of Science ®Google Scholar
• Gootenberg JS, Abudayyeh OO, Kellner MJ, et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360(6387):439–444. doi:10.1126/science.aaq0179.
   PubMed Web of Science ®Google Scholar
• Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using CRISPR-Cas13[J]. Science. 2018;360(6387):444–448. doi:10.1126/science.aas8836.
   PubMed Web of Science ®Google Scholar
• Li H, Dong X, Wang Y, et al. Sensitive and easy-read CRISPR strip for COVID-19 rapid point-of-care testing. CRISPR J. 2021;4(3):392–399. doi:10.1089/crispr.2020.0138.
   PubMedGoogle Scholar
• Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. doi:10.1002/hep.28156.
   PubMed Web of Science ®Google Scholar
• Hayer J, Jadeau F, Deléage G, et al. HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 2013;41(Database issue):D566–D570. doi:10.1093/nar/gks1022.
   PubMedGoogle Scholar
• Sciuto EL, Petralia S, Calabrese G, et al. An integrated biosensor platform for extraction and detection of nucleic acids. Biotechnol Bioeng. 2020;117(5):1554–1561.
   PubMed Web of Science ®Google Scholar
• Akram A, Islam S, Munshi SU, et al. Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay. J Viral Hepat. 2018;25(11):1306–1311. doi:10.1111/jvh.12931.
   PubMed Web of Science ®Google Scholar
• Florkowski C, Don-Wauchope A, Gimenez N, et al. Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making? Crit Rev Clin Lab Sci. 2017;54(7-8):471–494. doi:10.1080/10408363.2017.1399336.
   PubMed Web of Science ®Google Scholar
• Nelson PP, Rath BA, Fragkou PC, et al. Current and future point-of-care tests for emerging and New respiratory viruses and future perspectives. Front Cell Infect Microbiol. 2020;10:181.
   PubMed Web of Science ®Google Scholar
• Zou Y, Mason MG, Wang Y, et al. Nucleic acid purification from plants, animals, and microbes in under 30 seconds. PLoS Biol. 2017;15(11):e2003916. doi:10.1371/journal.pbio.2003916.
   PubMed Web of Science ®Google Scholar
• Pittella-Silva F, Chin YM, Chan HT, et al. Plasma or serum: which is preferable for mutation detection in liquid biopsy? Clin Chem. 2020;66(7):946–957. doi:10.1093/clinchem/hvaa103.
   PubMed Web of Science ®Google Scholar
• Pausch P, Al-Shayeb B, Bisom-Rapp E, et al. CRISPR-CasΦ from huge phages is a hypercompact genome editor. Science. 2020;369(6501):333–337. doi:10.1126/science.abb1400.
   PubMed Web of Science ®Google Scholar
• Jiang F, Doudna JA. CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505–529. doi:10.1146/annurev-biophys-062215-010822.
   PubMed Web of Science ®Google Scholar
• Kaminski MM, Abudayyeh OO, Gootenberg JS, et al. CRISPR-based diagnostics. Nat Biomed Eng. 2021;5(7):643–656. doi:10.1038/s41551-021-00760-7.
   PubMed Web of Science ®Google Scholar
• Maxmen A. Faster, better, cheaper: the rise of CRISPR in disease detection. Nature. 2019;566(7745):437), doi:10.1038/d41586-019-00601-3.
   PubMedGoogle Scholar
• Eisenstein M. Seven technologies to watch in 2022. Nature. 2022;601(7894):658–661. doi:10.1038/d41586-022-00163-x.
   PubMed Web of Science ®Google Scholar
• Freije CA, Myhrvold C, Boehm CK, et al. Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell. 2019;76(5):826–837.e11. doi:10.1016/j.molcel.2019.09.013.
   PubMed Web of Science ®Google Scholar
• Broughton JP, Deng X, Yu G, et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38(7):870–874.
   PubMed Web of Science ®Google Scholar
• Ding R, Long J, Yuan M, et al. Crispr/Cas12-based ultra-sensitive and specific point-of-care detection of HBV[J]. Int J Mol Sci, 2021, 22(9). doi:10.3390/ijms22094842.
   Web of Science ®Google Scholar
• Sinn DH, Lee J, Goo J, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology. 2015;62(3):694–701. doi:10.1002/hep.27889.
   PubMed Web of Science ®Google Scholar
• Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66(2):335–343. doi:10.1002/hep.28916.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40(7):1578–1589. doi:10.1111/liv.14482.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wu X, Zhou J, et al. Persistent Low level of hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol. 2020;18(11):2582–2591.e6. doi:10.1016/j.cgh.2020.03.001.
   PubMed Web of Science ®Google Scholar
• Zhang X, Tian Y, Xu L, et al. CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection. Hepatol Int. 2022;16(2):306–315. doi:10.1007/s12072-022-10311-0.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ke Y, Liu W, et al. A One-Pot toolbox based on Cas12a/crRNA enables rapid foodborne pathogen detection at attomolar level. ACS Sens. 2020;5(5):1427–1435. doi:10.1021/acssensors.0c00320.
   PubMed Web of Science ®Google Scholar